首页> 外文期刊>Cancer biology & therapy >Selective effects of a fiber chimeric conditionally replicative adenovirus armed with hep27 gene on renal cancer cell
【24h】

Selective effects of a fiber chimeric conditionally replicative adenovirus armed with hep27 gene on renal cancer cell

机译:携带hep27基因的纤维嵌合条件复制腺病毒对肾癌细胞的选择作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Adenoviruses mediated cancer gene therapies are widely investigated and show a promising effect on cancer treatment. However, efficient gene transfer varies among different cancer cell lines based on the expression of coxsakie adenovirus receptor (CAR). Hep27, a member of dehydrogenase/reductase (SDR) family, can bind to Mdm2, resulting in the attenuation of Mdm2-mediated p53 degradation. Here we constructed a fiber chimeric adenovirus carrying hep27 gene (F5/35-ZD55-Hep27), in which the fiber protein of 5-serotype adenovirus (Ad5) was substituted by that of 35-serotype adenovirus (Ad35), aiming to facilitate the infection for renal cancer cells and develop the role of hep27 in cancer therapy. We evaluated the CAR and CD46 (a membrane cofactor protein for Ad35) expression in four kinds of renal cancer cells and assessed the relationship between receptors and infection efficiency. 5/35 fiber-modified adenovirus had a much promising infectivity compared with Ad5-based vector in renal cancer cells. F5/35-ZD55-Hep27 had enhanced antitumor activity against human renal cancer cells compared to the other groups. Further, hep27 mediated p53 and cleaved-PARP upregulation and mdm2 downregulation was involved and caused increased apoptosis. Moreover, F5/35-ZD55-Hep27 significantly suppressed tumor growth in subcutaneous renal cancer cell xenograft models. Our data demonstrated that 5/35 fiber-modified adenovirus F5/35-ZD55-Hep27 transferred into renal cancers efficiently and increased p53 to induce cancer cell apoptosis. Thus 5/35 fiber-modified adenoviral vector F5/35-ZD55-Hep27 might a promising vector and antitumor reagent for renal cancer gene therapy.
机译:腺病毒介导的癌症基因疗法已被广泛研究,并显示出对癌症治疗的有希望的效果。但是,有效基因转移在不同癌细胞系之间的变化取决于coxsakie腺病毒受体(CAR)的表达。 Hep27是脱氢酶/还原酶(SDR)家族的成员,可以与Mdm2结合,导致Mdm2介导的p53降解减弱。在这里我们构建了带有hep27基因(F5 / 35-ZD55-Hep27)的纤维嵌合腺病毒,其中5种血清型腺病毒(Ad5)的纤维蛋白被35种血清型腺病毒(Ad35)的纤维蛋白替代,目的是促进感染可感染肾癌细胞,并发挥hep27在癌症治疗中的作用。我们评估了CAR和CD46(Ad35的膜辅助因子蛋白)在四种肾癌细胞中的表达,并评估了受体与感染效率之间的关系。与基于Ad5的载体相比,5/35纤维修饰的腺病毒在肾癌细胞中具有非常有希望的感染性。与其他组相比,F5 / 35-ZD55-Hep27具有增强的针对人肾癌细胞的抗肿瘤活性。此外,还涉及到hep27介导的p53和裂解的PARP上调以及mdm2下调,并导致凋亡增加。此外,F5 / 35-ZD55-Hep27在皮下肾癌细胞异种移植模型中显着抑制了肿瘤的生长。我们的数据表明5/35纤维修饰的腺病毒F5 / 35-ZD55-Hep27有效转移到肾癌中,并增加p53诱导癌细胞凋亡。因此,5/35纤维修饰的腺病毒载体F5 / 35-ZD55-Hep27可能是有前途的载体和抗肿瘤药物,用于肾癌基因治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号